Agaricus blazei Mycelial Liquid Culture Extract Containing Eritadenine Improves Benign Prostatic Hyperplasia-related Biochemical Markers in RWPE-1 Cells through Anti-inflammatory and Anti-oxidative Actions

Agaricus blazei mycelial liquid culture extract (ABMLCE) promoted the production of testosterone (TS) in TM-3 mouse Leydig testis cells. Now, we report that ABMLCE containing eritadenine (EA) as a minor constituent (15.3 mg/100 g) reduced $5{\alpha}-reductase$ 2 ($5{\alpha}-R2$) enzyme activity and dihydrotestosterone (DHT) content which are key constituents for the benign prostatic hyperplasia (BPH) inductions. RWPE-1 prostate cells were grown in a Keratinocyte serum-free medium (K-SFM) containing ABMLCE (0~50 ppm), EA (0~10 ppm,), and finasteride (FS $10{\mu}M$: a positive control) in a 24-well plate for 24 hr. Supernatants collected from cell-cultured media were used for the assay of $5{\alpha}-R2$, superoxide dismutase (SOD), catalase (CAT) and cyclooxygenase-2 (COX-2) enzyme activities, and for TS, DHT, tumor necrosis $factor-{\alpha}$ ($TNF-{\alpha}$) and $interleukin-1{\beta}$ ($IL-1{\beta}$) contents by their assay kits. The $5{\alpha}-R2$ activity and DHT content were proportionally reduced (p<0.05) to concentrations of ABMLCE. The SOD and CAT enzyme activities were significantly (p<0.05) elevated concomitant with ABMLCE concentrations, while COX-2, $TNF-{\alpha}$ and $IL-1{\beta}$ showed reverse results (p<0.05). Similarly, the effects of EA were similar to those of ABMLCE. Efficacies of ABMLCE 50 ppm and EA 10 ppm in $5{\alpha}-R2$ and DHT reduction were similar to those of $10{\mu}M$ FS. These results suggest that ABMLCE and EA reduced $5{\alpha}-R2$ and DHT through their anti-inflammatory and anti-oxidative actions. This implies that ABMLCE containing EA could be a beneficial material in the cure of BPH in humans.

RWPE-1 전립선세포에서 eritadenine을 함유한 신령버섯균사체 액체배양물의 항염증효과 및 항산화효과에 의한 전립선비대증 관련 biochemical marker 개선 효과

신령버섯균사체 액체배양 추출물(Agaricus blazei mycelial liquid culture extract, ABMLCE)은 TM-3 mouse Leydig 고환세포에서 testosterone (TS)의 생성을 촉진하였다. 이번 연구에서는 eritadenine (EA, 15.3 mg/100 g)을 함유한 ABMLCE가 RWPE-1 전립선세포에서 전립선비대증(Benign prostatic hyperplasia, BPH) 관련 핵심 효소인 $5{\alpha}-reductase$ 2 ($5{\alpha}-R2$) 활성과 dihydrotestosterone (DHT) 함량을 감소시켰음을 보고한다. RWPE-1 전립선 세포는 24-well plate에서 ABMLCE (0~50 ppm), EA (0~10 ppm,), finasteride (FS $10{\mu}M$: positive Control)를 함유한 Keratinocyte serum-free medium (K-SFM)에서 24시간 배양하였다. 시료처리 세포배양액에 대해 $5{\alpha}-R2$, superoxide dismutase (SOD), catalase (CAT), cyclooxygenase-2 (COX-2) 효소활성, TS, DHT, tumor necrosis $factor-{\alpha}$ ($TNF-{\alpha}$)와 $interleukin-1{\beta}$ ($IL-1{\beta}$)를 assay kit를 사용하여 분석하였다. $5{\alpha}-R2$ 활성과 DHT 함량은 ABMLCE의 농도 의존적으로 유의성(p<0.05) 있게 감소되었고, SOD와 CAT 효소활성은 유의성(p<0.05) 있게 증가되었다. 반면에 COX-2 활성과 $TNF-{\alpha}$ 및 $IL-1{\beta}$의 함량은 감소되었다(p<0.05). 마찬가지로 EA의 효과도 ABMLCE 효과와 유사하였다. ABMLCE 50 ppm과 EA 10 ppm의 $5{\alpha}-R2$ 및 DHT 감소효과는 FS $10{\mu}M$ 효과와 유사하였다. 이들 결과는 ABMLCE와 EA는 항염증효과와 항산화효과를 통하여 BPH 유발 핵심 인자인 $5{\alpha}-R2$ 효소활성과 DHT 함량을 감소시켰다. 또한 이 결과는 EA를 함유하는 ABMLCE는 인체 BPH 개선 소재로 활용할 수 있음을 의미한다.